PO-1279 PFS and recurrence patterns after CCRT with durvalumab for stage III and recurrent NSCLCN. Kishi,Y. Matsuo,T. Shintani, M. Ogura,T. Mitsuyoshi,N. Araki, K. Fujii, S. Okumura,K. Nakamatsu,T. Kishi,T. Atsuta,T. Sakamoto,S. Otsu, T. Katagiri,M. Narabayashi,S. Fujishiro,Y. Iizuka,H. Ozasa,T. MizowakiRadiotherapy and Oncology(2022)引用 0|浏览10暂无评分关键词recurrent nsclc,durvalumab,ccrtAI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要